PRNewswire
- ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatmentLONDON, June 28, 2025 /PRNewswire/ — A team of international scientists has made a major leap forward in diabetes research… Read more »
- ESOT-Kongress 2025: Wissenschaftler schaffen funktionale Langerhans-Inseln im 3D-Druckverfahren für die Behandlung von Typ-1-DiabetesLONDON, 28. Juni 2025 /PRNewswire/ — Einem Team internationaler Wissenschaftler ist ein großer Fortschritt in der Diabetesforschung gelungen, indem sie… Read more »
- Congrès 2025 de l'ESOT : des scientifiques créent des îlots humains fonctionnels pour le traitement du diabète de type 1 grâce aux avancées de l'impression 3DLONDRES, 28 juin 2025 /PRNewswire/ — Une équipe de scientifiques internationaux a fait un grand pas en avant dans la… Read more »
- Congreso ESOT 2025: Científicos crean islotes humanos funcionales mediante impresión 3D-Congreso ESOT 2025: Científicos crean islotes humanos funcionales mediante impresión 3D, un avance para el tratamiento de la diabetes tipo… Read more »
- ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatmentLONDON, June 28, 2025 /PRNewswire/ — A team of international scientists has made a major leap forward in diabetes research… Read more »
Zentiva fordert Pause – Reparatur – Wiederaufnahme der Richtlinie über die Behandlung von kommunalem Abwasser (UWWTD)BRÜSSEL und PRAG, 28. Juni 2025 /PRNewswire/ — Während sich die EU an die globalen geopolitischen Spannungen anpasst und sich… Read more »- FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's diseaseApproval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant… Read more »
- FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's diseaseApproval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant… Read more »
- Zentiva appelle à une pause, une révision et une relance de la Directive relative au Traitement des Eaux Urbaines Résiduaires (TEUR)BRUXELLES et PRAGUE, 27 juin 2025 /PRNewswire/ — Alors que l’UE s’adapte aux tensions géopolitiques mondiales et renouvelle son engagement… Read more »
- Zentiva pide una pausa, reparación y relanzamiento de la UWWTD-Zentiva pide una pausa, reparación y relanzamiento de la Directiva sobre el Tratamiento de Aguas Residuales Urbanas (UWWTD) BRUSELAS y… Read more »
Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ — The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024… Read more »
Debut Named to TIME's List of the TIME100 Most Influential Companies 2025Debut’s inclusion in the TIME100 is the first time a biotech beauty company has made the list since its inception.… Read more »
GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual MeetingDifferences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma’s manufacturing process reduces FXIa to… Read more »
O'Shaughnessy Ventures Awards $100K Fellowship to Connect Living Cells to the InternetJan Jedryszek to engineer nanodevice connecting biological cells to digital systems GREENWICH, Conn., June 27, 2025 /PRNewswire/ — O’Shaughnessy Ventures… Read more »
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease ChoreaPatient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placebo Findings to be… Read more »
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorderPhase 3 study met primary and most key secondary clinical endpoints This marks the third developmental and epileptic encephalopathies (DEE)… Read more »- Regenics Appoints Brynjólfur Gísli Eyjólfsson as Chair of the BoardOSLO, Norway, June 27, 2025 /PRNewswire/ — Regenics AS, a Norwegian biotech company developing advanced marine-based wound care products, announces… Read more »
ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene TherapyHOPEWELL, N.J., June 27, 2025 /PRNewswire/ — ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and… Read more »- Zentiva calls for Pause – Repair – Relaunch of the Urban Wastewater Treatment Directive (UWWTD)BRUSSELS and PRAGUE, June 27, 2025 /PRNewswire/ — As the EU adapts to global geopolitical tensions and renews its focus… Read more »
- Zentiva calls for Pause – Repair – Relaunch of the Urban Wastewater Treatment Directive (UWWTD)BRUSSELS and PRAGUE, June 27, 2025 /PRNewswire/ — As the EU adapts to global geopolitical tensions and renews its focus… Read more »